DLBCL
Feature
ASTRO Pushes Return to Direct Supervision in RT: Needed or ‘Babysitting’?
But some radiation oncologists do not agree with the proposal to move back to direct in-person supervision only.
Conference Coverage
High Marks for New CAR T Toxicity Grading Tool
A real-world study demonstrates the benefits of a new grading system to assess hematotoxicities across disease types following CAR T-cell...
News from the FDA/CDC
FDA Removes Harmful Chemicals From Food Packaging
The “major source of dietary exposure to PFAS from food packaging” is being eliminated.
Feature
Are Food Emulsifiers Associated With Increased Cancer Risk?
Food emulsifiers are among the most widespread food additives.
Feature
Democratic Lawmakers Press Pfizer on Chemotherapy Drug Shortages
The company, which said in May that it was working to assuage critical shortages of methotrexate, carboplatin and cisplatin, is being asked to...
Commentary
Unleashing Our Immune Response to Quash Cancer
“It’s astounding how devious cancer cells and tumor tissue can be.”
Conference Coverage
Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T
Awaiting CAR T therapy, patients with complete response to interim chemo show better outcomes with subsequent autologous transplantation, compared...
News
FDA OKs new agent to block chemotherapy-induced neutropenia
Efbemalenograstim has been approved by the FDA to combat infections in adults being treated for nonmyeloid cancers.
News
FDA panel voices concerns over 2 lymphoma accelerated approvals
FDA’s ODAC committee pressed for resolution on whether 2 lymphoma drugs, long on the U.S. market, actually deliver significant benefits to...
Conference Coverage
FDA’s Project Optimus aims to transform early cancer research
Q & A with an expert on how the FDA’s Project Optimus targets toxicity and how it could spell the end of traditional dose-escalation trials....
Conference Coverage
DLBCL treatment options: CAR T outperforms ASCT
Relapsed and refractory DLBCL patients treated with CAR T-cell therapy achieved better outcomes than with autologous stem cell transplants.